DA, Q., N, L., PF, C., M, M., P, P., RC, G., . . . G, S. (2023). Tafasitamab and lenalidomide in large B-cell lymphoma: Real-world outcomes in a multicenter retrospective study. Blood, 142(26), 2327. https://doi.org/10.1182/blood.2023021274
Chicago Style (17th ed.) CitationDA, Qualls, et al. "Tafasitamab and Lenalidomide in Large B-cell Lymphoma: Real-world Outcomes in a Multicenter Retrospective Study." Blood 142, no. 26 (2023): 2327. https://doi.org/10.1182/blood.2023021274.
MLA (9th ed.) CitationDA, Qualls, et al. "Tafasitamab and Lenalidomide in Large B-cell Lymphoma: Real-world Outcomes in a Multicenter Retrospective Study." Blood, vol. 142, no. 26, 2023, p. 2327, https://doi.org/10.1182/blood.2023021274.
Warning: These citations may not always be 100% accurate.
